Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Acute Lymphoblastic Leukemia – Unmet Need – Unmet Need – Relapsed or Refractory Philadelphia Chromosome-Negative ALL (US/EU)
Relapsed / refractory (R/R) Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) patients have a poor prognosis. No standard of care has been established for relapsed / refractory…
Acute Lymphoblastic Leukemia – Landscape & Forecast – Disease Landscape & Forecast
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and…
Monoclonal Gammopathy of Undetermined Significance – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Chronic Myeloid Leukemia – Current Treatment – Current Treatment: Physician Insights – Chronic Myeloid Leukemia (US)
The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…
Chronic Myeloid Leukemia – Current Treatment – Treatment Sequencing – Chronic Myeloid Leukemia (US)
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to position…
Non-Hodgkin’s Lymphoma – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory DLBCL (US/EU)
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
